Plasmapheresis in neuropsychiatric involvement in systemic lupus erythematosus
DOI:
https://doi.org/10.51481/amc.v61i3.1040Keywords:
systemic erythematosus lupus, plasmapheresis, neuropsychiatric lupusAbstract
One of the most feared clinical presentations of systemic lupus erythematosus is neuropsychiatric involvement, specially associated psychosis. Diagnostic definitions are not well stablished to date however clinical suspicion and case registry has been increasing over time. There is scarce evidence regarding correct therapeutic approach to psychiatric presentations of systemic lupus erythematosus, however, it is well known that it is consequence of noxious autoimmune activity of the brain without structural compromise. Corticosteroids, cyclophosphamide and rituximab are part of the pharmacologic tools available. We present a case a 13 year old adolescent with new onset systemic lupus erythematosus in whom one of the principal initial concerns was how to address intense neuropsychiatric manifestations and specially refractory psychosis. First, high doses of steroid boluses were offered with no benefit in psychiatric symptoms, then cyclophosphamide was administered, with no success. Finally, therapeutic plasma exchange was offered to the patient with rapid clinical improvement. A total of 4 sessions of plasmapheresis with human albumin were done.
Downloads
References
. Liang M, Corzillius M, Sang-Cheol B, Lew R, Fortin P, Gordon C. The american college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599-608.
Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016;76:459-83.
Faria R, Gonçalves J, Dias R. Neuropsychiatric systemic lupus erythematosus involvement: towards a tailored approach to our patients? Rambam Maimonides Med J. 2017;8: e0001.
Luyendijk J, Steens SCA, Ouwendijk WJN, Steup-Beekman GM, Bollen ELEM, van der Grond J, et al. Neuropsychiatric systemic lupus erythematosus: Lessons learned from magnetic resonance imaging. Arthritis Rheum. 2011; 63:722-32.
Joseph FG, Scolding NJ. Neurolupus. Pract Neurol. 2010;10:4-15.
Baraldi O, Chiocchini AL, Comai G, Cravedi P, Angeletti A, Manna GL. Rituximab as first-line therapy in severe lupus erythematosus with neuropsychiatric and renal Involvement: A case-report and review of the literature. J Clin Case Rep [Internet]. 2017;7(10). Disponible en: https://www. omicsonline.org/open-access/rituximab-as-firstline-therapy-in-severe-lupuserythematosus-with-neuropsychiatric-and-renal-involvement-a-casereport-andreview-o-2165-7920-10001033-95332.html
Bartolucci P, Bréchignac S, Cohen P, Le Guern V, Guillevin L. Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus. 2007;16:817-22.
Bambauer R, Latza R, Burgard D, Schiel R. Therapeutic apheresis in immunologic renal and neurological diseases. Ther Apher Dial. 2017; 21:6-21.
Weinstein, Robert. Therapeutic apheresis in neurological disorders. J Clin Apheresis. 2000;15:74-128.
Cortese I, Cornblath DR. Therapeutic plasma exchange in neurology: 2012. J Clin Apheresis. 2013; 28: 16-9.
Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. J Int Soc Apher. 2003; 7:173-82.
Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the use of therapeutic apheresis in clinical practiceevidence-based approach from the writing committee of the american society for apheresis: The seventh special issue: Therapeutic apheresis-guidelines 2016. J Clin Apheresis. 2016; 3: 149-338.
Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016; 76:459-83.
W Jan JG. MRI and the brain in systemic lupus erythematosus. Lupus.
;12:891-3.
Downloads
Published
Versions
- 2019-08-29 (2)
- 2019-08-29 (1)
Issue
Section
License
Copyright (c) 2019 Acta Médica Costarricense

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)



